Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …

Type 2 diabetes is increasingly becoming a worldwide epidemic. Currently there is much
focus on the glucagon-like peptide-1 (GLP-1) peptide hormone as the basis for a potential …

Abstract Glucagon-like peptide 1 (GLP-1) was discovered as an incretin (insulinotropic gut)
hormone. Biological actions of GLP-1 in healthy and type 2 diabetic subjects include (a) …

Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

Background Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and
glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Post‐translational proteolytic processing of the preproglucagon gene in the gut results in the
formation of glucagon‐like peptide 1 (GLP‐1). Owing to its glucose‐dependent …

Cardiovascular (CV) disease is the leading cause of death and morbidity in patients with
type 2 diabetes. Five CV risk factors (blood pressure, resting heart rate, body weight …

Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2
diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated …

Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted primarily from the intestinal
L-cells in response to meals, modulates nutrient homeostasis via actions exerted in multiple …